Review Article

Hypopharyngeal and Cervical Esophageal Carcinoma: Diagnostic and Therapeutic Approach

Manuel Alejandro Ramírez Solano[1*], Jimena María Hidalgo Retana[2], Antony Freizer Tenorio Fallas[3], Mariana Bolaños Castro[4], Kristian Lewis Thomas[5], Lola Dive Chagnon[6]

[1]Medical Doctor, Caja Costarricense de Seguro Social (CCSS), Cartago, Costa Rica
[2]Medical Doctor, Caja Costarricense de Seguro Social (CCSS), San José, Costa Rica
[3]Medical Doctor, EBAIS Paso Ancho-San Sebastián, San José, Costa Rica
[4]Medical Doctor, San Juan de Dios Hospital, San José, Costa Rica
[5]Medical Doctor, Caja Costarricense de Seguro Social (CCSS). Limón, Costa Rica
[6]Medical Doctor, Independent Researcher, Heredia, Costa Rica
[*]Corresponding author email: **maramirez83@hotmail.com**

International Archives of Integrated Medicine, Vol. 13, Issue 4, April, 2026.
Available online at http://iaimjournal.com/
ISSN: 2394-0026 (P) **ISSN: 2394-0034 (O)**
Received on: 14-3-2026 **Accepted on:** 9-4-2026
Source of support: Nil **Conflict of interest:** None declared.

DOI: **10.5281/zenodo.19809499**

How to cite this article: Manuel Alejandro Ramírez Solano, Jimena María Hidalgo Retana, Antony Freizer Tenorio Fallas, Mariana Bolaños Castro, Kristian Lewis Thomas, Lola Dive Chagnon. Hypopharyngeal and Cervical Esophageal Carcinoma: Diagnostic and Therapeutic Approach. Int. Arch. Integr. Med., 2026; 13(4): 32-48.

Abstract

Hypopharyngeal and cervical esophageal carcinomas are aggressive malignancies of the upper aerodigestive tract characterized by complex anatomical relationships, early lymphatic dissemination, and poor overall prognosis. The hypopharynx extends from the hyoid bone to the inferior border of the cricoid cartilage and includes the pyriform sinus, posterior pharyngeal wall, and postcricoid region, while the cervical esophagus begins at the cricopharyngeus muscle and extends to the thoracic inlet. Their anatomical proximity facilitates direct tumor extension, and invasion into the cervical esophagus significantly worsens survival outcomes. Rich lymphatic drainage to cervical, paratracheal, and mediastinal nodes explains the high frequency of early nodal metastasis, with extra-capsular spread representing a marker of aggressive disease. Tobacco and alcohol consumption are the principal risk factors, with a clear synergistic effect that markedly increases cancer risk. Squamous

cell carcinoma accounts for more than ninety percent of cases and commonly demonstrates submucosal extension, lymphovascular invasion, and early regional spread. Molecular alterations such as TP53 mutations, epidermal growth factor receptor overexpression, and programmed death-ligand 1 expression further characterize tumor aggressiveness and therapeutic targets. Clinical presentation is often subtle in early stages, with mild dysphagia and throat discomfort, leading to delayed diagnosis. Advanced disease manifests with severe dysphagia, cervical lymphadenopathy, weight loss, airway compromise, and malnutrition. Diagnosis relies on comprehensive clinical examination, endoscopic evaluation, imaging studies, and histologic confirmation. Management requires a multidisciplinary approach integrating surgery, chemoradiotherapy, and reconstruction. Despite therapeutic advances, advanced-stage disease remains associated with poor survival and significant functional morbidity, underscoring the importance of early detection, accurate staging, and individualized treatment strategies.

Key words

Hypopharynx, Cervical esophagus, Squamous cell carcinoma, Lymphatic metastasis, Chemoradiotherapy, Organ preservation.

Introduction

Hypopharyngeal squamous cell carcinoma with invasion into the cervical esophagus represents a particularly aggressive clinical entity and is consistently associated with a poor prognosis. The presence of invasion into the cervical esophagus has been shown to significantly compromise both disease-free and overall survival. Reported five-year disease-free and overall survival rates in patients with such invasion are 21.7% and 13.1%, respectively, compared with substantially higher rates of 54.1% and 53.8% in patients without cervical esophageal involvement. These findings underscore the negative prognostic impact of contiguous spread and highlight the importance of accurate staging and early detection [1].

In the context of cervical esophageal carcinoma, definitive chemoradiotherapy has emerged as a relevant therapeutic modality. Patients treated with this approach demonstrate a two-year overall survival rate of 58.7% and a progression-free survival rate of 47%, supporting chemoradiotherapy as a viable and potentially effective treatment option in selected cases. Nevertheless, outcomes vary according to tumor characteristics and patient-related factors, reinforcing the need for individualized treatment planning [2].

Postcricoid carcinoma, a recognized subtype of hypopharyngeal carcinoma, further illustrates the aggressive behavior of tumors in this anatomical region. This subtype is characterized by high rates of local failure and considerable treatment-related morbidity, with an overall survival rate of approximately 50%. The presence of lymph node metastasis and the occurrence of neck recurrence have been identified as significant prognostic determinants, directly influencing long-term outcomes [3].

Surgical management remains a cornerstone in selected patients, particularly in cases of hypopharyngeal or laryngeal cancer invading the cervical esophagus. Total pharyngolaryngoesophagectomy with gastric pull-up reconstruction is commonly performed and has been shown to be technically feasible and relatively safe. However, despite acceptable perioperative outcomes, long-term survival remains limited, with reported five-year overall survival and disease-free survival probabilities of 22.6% and 22.7%, respectively [4].

For resectable cervical esophageal cancer, high-dose chemoradiotherapy has been recommended

over primary surgery, as it has demonstrated superior loco-regional failure-free survival and overall survival without a corresponding increase in toxicity [5]. In addition, neoadjuvant chemoradiotherapy followed by surgery has shown potential survival advantages compared with definitive chemoradiotherapy alone in cervical and upper-third esophageal cancers, with improved median overall survival reported in comparative analyses [6]. Despite these therapeutic advances, significant challenges persist. The aggressive nature of hypopharyngeal and cervical esophageal carcinomas, combined with their frequent presentation at advanced stages, complicates treatment planning and limits curative potential. The anatomical complexity of the region and its proximity to critical structures increase the risk of postoperative complications and long-term functional deficits [6]. Consequently, multimodal treatment approaches that integrate surgery, radiation, and chemotherapy are often required, although they are associated with considerable morbidity. In this context, therapeutic decisions must carefully balance oncologic control with preservation of speech, swallowing, and overall quality of life [7].

The rarity of these malignancies and their underrepresentation in large prospective clinical trials hinder the development of standardized treatment protocols. As a result, management frequently relies on the expertise of multidisciplinary teams and the extrapolation of data from related tumor sites [8].

The objective of this article is to critically examine hypopharyngeal and cervical esophageal carcinoma, emphasizing their clinical significance, prognostic factors, diagnostic strategies, and current therapeutic approaches, with the aim of integrating available evidence to support multidisciplinary decision-making and optimize both oncologic control and functional outcomes.

Methodology

This manuscript was developed as a structured narrative review aimed at providing an updated and clinically integrated analysis of hypopharyngeal and cervical esophageal carcinoma, with particular emphasis on prognostic determinants, diagnostic strategies, and contemporary therapeutic approaches. The review was conducted in accordance with the SANRA (Scale for the Assessment of Narrative Review Articles) framework and followed a predefined methodological protocol established prior to literature screening. Given the clinical heterogeneity of these tumors and the variability in staging systems and treatment paradigms, a narrative interpretative synthesis was selected over quantitative pooling in order to integrate anatomical, oncologic, and functional considerations into a coherent and clinically applicable framework. Special attention was given to the impact of cervical esophageal invasion on survival, the role of multimodal therapy, organ-preservation strategies, and reconstructive approaches in advanced disease. The objective was to provide a structured synthesis capable of supporting multidisciplinary decision-making in complex upper aerodigestive tract malignancies.

A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science, including peer-reviewed articles published in English or Spanish between January 2020 and December 2026. The final search was performed in December 2026. This timeframe was selected to capture contemporary advances in chemoradiotherapy protocols, surgical reconstruction techniques, immunotherapy integration, and updated staging recommendations. Foundational studies were incorporated when necessary to contextualize pathophysiological mechanisms or historical treatment evolution. The search strategy combined MeSH and free-text terms using Boolean operators related to hypopharyngeal carcinoma, cervical esophageal carcinoma, squamous cell carcinoma, cervical esophageal invasion, chemoradiotherapy,

pharyngolaryngoesophagectomy, organ preservation, neoadjuvant therapy, survival outcomes, and reconstruction techniques. Searches were conducted in titles and abstracts as well as indexed subject headings to maximize sensitivity.

The initial search yielded 212 records. After removal of duplicates, 168 articles remained for title and abstract screening. Of these, 97 underwent full-text evaluation, and 54 studies were included in the final synthesis. Selection was performed independently by two authors, with disagreements resolved through discussion and consensus. Exclusion criteria comprised non–peer-reviewed publications, isolated case reports, editorials without outcome data, purely technical surgical descriptions lacking oncologic results, redundant datasets, and studies not directly addressing prognostic impact, diagnostic evaluation, or therapeutic outcomes in hypopharyngeal or cervical esophageal carcinoma.

Eligible studies included randomized controlled trials, large observational cohorts, systematic reviews, meta-analyses, expert consensus statements, and contemporary international guidelines from head and neck oncology, thoracic surgery, and radiation oncology societies. Priority was assigned to multicenter investigations, studies with standardized TNM staging definitions, and research evaluating survival outcomes, loco-regional control, functional results, and treatment-related morbidity. Extracted variables included study design, tumor location and stage, presence of cervical esophageal invasion, treatment modality, reconstruction technique when applicable, survival metrics (overall survival and disease-free survival), recurrence patterns, and reported complications. Methodological quality and internal validity were assessed narratively, considering risk of bias, sample size, follow-up duration, consistency of staging criteria, and reproducibility of reported outcomes. In cases of conflicting evidence, greater interpretative weight was assigned to higher-level evidence and guideline-supported recommendations.

Reference lists of included studies were manually screened to identify additional relevant publications. Given its narrative design, this review is subject to potential selection bias and does not provide pooled quantitative estimates. Artificial intelligence–based tools were used exclusively to assist in literature organization and structural coherence, whereas critical appraisal, synthesis, and final interpretation were conducted independently by the authors to preserve methodological rigor.

Anatomy and Patterns of Spread

The hypopharynx extends anatomically from the hyoid bone to the inferior border of the cricoid cartilage and is subdivided into the pyriform sinus, the posterior pharyngeal wall, and the postcricoid region. Among these subsites, the pyriform sinus represents one of the most common locations for primary tumor development. Its anatomical configuration and rich lymphatic network favor early regional dissemination, which frequently results in advanced-stage disease at the time of diagnosis [4].

Inferiorly contiguous with the hypopharynx, the cervical esophagus begins at the level of the cricopharyngeus muscle and extends to the thoracic inlet. The anatomical proximity between these structures facilitates direct tumor extension, and invasion into the cervical esophagus constitutes a particularly relevant pathological event in hypopharyngeal squamous cell carcinoma. The presence of cervical esophageal invasion has been shown to significantly influence both prognosis and treatment outcomes, reinforcing the importance of precise anatomical assessment during staging and therapeutic planning [1].

The patterns of spread of tumors arising in this region are closely linked to their complex lymphatic drainage. The primary nodal basins

involved include cervical levels II through IV, as well as paratracheal and upper mediastinal nodes. Early nodal metastasis is common in hypopharyngeal carcinoma, and lymph node status has been consistently identified as a significant prognostic factor for overall survival [3, 9]. The extensive dissemination of nodal disease is facilitated by abundant lymphatic flow and the anatomical location of these tumors, allowing metastatic spread to extend from the cervical region to more distal fields, including abdominal nodal stations [10].

Beyond simple nodal involvement, the biological behavior of metastatic disease further influences prognosis. Lymph node metastasis represents a critical determinant of survival, particularly when associated with extra-capsular spread, which is recognized as a hallmark of aggressive tumor phenotype in head and neck cancers. The presence of extra-capsular spread correlates with higher recurrence rates and significantly poorer survival outcomes, thereby shaping risk stratification and adjuvant treatment decisions [11].

These anatomical and pathological considerations directly inform therapeutic strategies. In hypopharyngeal carcinoma, upfront neck dissection followed by concurrent chemoradiotherapy has demonstrated improved neck control rates and enhanced disease-free survival, particularly in patients with significant nodal burden [9]. In more advanced cases involving extensive local invasion, total pharyngolaryngoesophagectomy with gastric pull-up reconstruction is frequently performed. Although this approach remains technically feasible, it is associated with substantial morbidity and limited long-term survival, reflecting the advanced stage and biological aggressiveness of the disease [4].

Radiotherapy planning also plays a pivotal role in management, and meticulous delineation of target volumes is essential to optimize oncologic control while minimizing toxicity. The involvement of specialized radiological expertise may contribute to more precise targeting, thereby reducing unnecessary radiation exposure and limiting treatment-related side effects [12]. Furthermore, in cases of squamous cell carcinoma of unknown primary site, selective irradiation of the oropharynx and nasopharynx, while excluding the larynx and hypopharynx, has proven effective in preventing recurrence, highlighting the importance of tailored radiation strategies based on anatomical and clinical considerations [13].

Epidemiology and Risk Factors

Tobacco use constitutes one of the principal risk factors for esophageal squamous cell carcinoma, with consistent evidence demonstrating an increased risk associated with both smoking and the use of smokeless tobacco. Population-based studies conducted in Tanzania, Malawi, and Kenya have reported significantly elevated risks among tobacco users, with odds ratios of 3.09, 2.45, and 1.37, respectively, thereby confirming the strong association between tobacco exposure and disease development in diverse geographic contexts [14]. Similarly, data from Northeast India indicate that tobacco consumption, particularly when combined with betel nut use, markedly increases the risk of esophageal cancer, with an odds ratio of 3.47, further reinforcing the carcinogenic impact of these exposures [15].

In addition to tobacco, alcohol consumption represents another major and independently established risk factor for esophageal cancer. A study conducted in South Korea demonstrated that alcohol intake significantly increased the risk of esophageal cancer, with an adjusted odds ratio of 1.89 [16]. Complementary findings from the United States revealed that alcohol consumption accounts for a substantial proportion of esophageal squamous cell carcinoma cases, with population-attributable fractions ranging from 26.6% to 28.7% among men, underscoring its considerable contribution to disease burden [17].

Importantly, the combined exposure to tobacco and alcohol exerts a synergistic effect that further amplifies cancer risk. A systematic review and meta-analysis confirmed the markedly increased risk observed when both factors are present simultaneously, highlighting the multiplicative interaction between these carcinogens and emphasizing the importance of integrated prevention strategies [18]. In Northeast India, the highest risks were documented among individuals exposed to a combination of betel nut, tobacco, and alcohol, with odds ratios of 7.84 and 2.84 reported for different exposure patterns, illustrating the cumulative and synergistic carcinogenic potential of these substances [15].

Beyond substance-related exposures, nutritional factors also play a relevant role in esophageal carcinogenesis. Diets characterized by low intake of fruits and vegetables have been associated with an increased risk of esophageal cancer, and epidemiological analyses have identified inadequate consumption of these protective foods as a significant contributor to overall disease burden. Although less extensively studied in the referenced contexts, prior radiation exposure and the field cancerization phenomenon - defined by the development of multiple primary tumors within the aerodigestive tract - are additionally recognized as contributing factors in esophageal malignancies [19].

These risk factors collectively help explain observed epidemiological trends. The global burden of esophageal cancer has risen in recent decades, with notable increases in both incidence and mortality rates, particularly among males. This upward trend has been attributed largely to the sustained prevalence of smoking and alcohol consumption across multiple populations [19]. Consistent with this pattern, data from Taiwan demonstrate a significant rise in the incidence of esophageal squamous cell carcinoma over past decades, closely correlating with the widespread use of tobacco, alcohol, and betel nut, thereby illustrating the direct relationship between behavioral risk factors and population-level disease dynamics [20].

Histopathology and Molecular Characteristics

Squamous cell carcinoma constitutes the predominant histological subtype in both hypopharyngeal and cervical esophageal malignancies, accounting for more than 90% of cases. This neoplasm is characterized by the proliferation of keratinizing or non-keratinizing squamous cells and reflects the direct impact of chronic mucosal exposure to carcinogenic factors [21, 22]. It’s overwhelming prevalence in these anatomical regions underscores its central role in shaping diagnostic algorithms, staging considerations, and therapeutic strategies. In contrast, adenocarcinoma is rare in the cervical esophagus. When present, it is more typically associated with Barrett’s esophagus in other segments of the esophagus and therefore represents an uncommon histologic finding in the cervical portion [21].

Beyond histologic classification, several pathological features critically influence tumor behavior and clinical outcomes. Submucosal extension is frequently observed in esophageal carcinomas and reflects the propensity of the tumor to infiltrate beyond the mucosal layer into the submucosa. This pattern of spread complicates surgical resection by obscuring true tumor margins and increasing the likelihood of residual disease. In addition, perineural invasion is documented in a significant proportion of esophageal squamous cell carcinoma cases and is commonly associated with advanced tumor stages and concomitant lymphovascular invasion. Although perineural invasion correlates with more aggressive disease characteristics, it has not been identified as an independent prognostic factor for survival [23].

Lymphovascular invasion represents another critical pathological determinant, facilitating the dissemination of malignant cells to regional lymph nodes and distant sites. Its presence

contributes directly to early regional metastasis and reflects an enhanced capacity for systemic spread [23]. Consistent with these pathological features, hypopharyngeal and cervical esophageal carcinomas frequently exhibit early metastasis to regional lymph nodes, necessitating comprehensive staging and integrated treatment strategies to address both local and nodal disease [21, 24].

At the molecular level, several alterations further characterize the biological aggressiveness of these tumors. Mutations in the TP53 gene are highly prevalent in esophageal squamous cell carcinoma and have been associated with poor prognosis as well as resistance to therapy, thereby influencing both survival outcomes and therapeutic responsiveness. Overexpression of the epidermal growth factor receptor is another common molecular alteration in these carcinomas, providing a potential target for molecularly directed therapies and reflecting dysregulated proliferative signaling pathways [22, 25]. Additionally, expression of programmed death-ligand 1 carries important therapeutic implications, as it constitutes a target for immune checkpoint inhibitors such as nivolumab and pembrolizumab, which have demonstrated promising activity in advanced esophageal cancers [21, 26].

Clinical Presentation

The early clinical manifestations of hypopharyngeal and cervical esophageal carcinomas are frequently subtle and nonspecific, which contributes to delayed diagnosis. Mild dysphagia is often among the first symptoms reported by patients and represents a common early manifestation of both esophageal and hypopharyngeal malignancies. At this stage, swallowing difficulty is typically minimal and may be intermittent, leading patients to attribute it to benign conditions such as gastroesophageal reflux or transient throat irritation [27, 28].

In addition to dysphagia, patients may experience persistent throat discomfort or a globus sensation, described as a feeling of a lump in the throat. These symptoms are generally vague and lack alarming characteristics, which further delays clinical suspicion. Because such sensations are commonly associated with functional or inflammatory disorders, they often fail to prompt immediate diagnostic investigation, thereby contributing to later-stage detection [29].

As the disease advances, symptoms typically intensify and become more specific. Dysphagia progressively worsens and is often accompanied by odynophagia, reflecting deeper tumor infiltration and luminal compromise. The increasing severity of swallowing difficulty can significantly impair oral intake and quality of life [30, 31]. Concurrently, hoarseness may develop as a result of recurrent laryngeal nerve involvement, indicating local extension of the tumor. Referred otalgia may also occur, arising from shared neural pathways between the throat and the ear, and represents another clinical sign suggestive of more advanced local disease [32].

Further progression is frequently marked by cervical lymphadenopathy, reflecting regional nodal metastasis, and by unintended weight loss, which signals systemic involvement and increased metabolic demand associated with malignancy. The presence of enlarged cervical lymph nodes and significant weight reduction is commonly associated with more advanced stages and poorer outcomes [1, 33].

In advanced disease, complications become more severe and potentially life-threatening. Tumor enlargement may lead to airway compromise, resulting in partial obstruction and increased risk of aspiration. Aspiration events can precipitate respiratory complications and further deteriorate clinical status [28, 34]. At the same time, persistent and severe dysphagia and odynophagia frequently culminate in malnutrition. Nutritional deterioration not only reflects disease severity but also exacerbates overall health decline and

complicates tolerance to oncologic treatment, thereby negatively influencing prognosis [35].

Diagnostic Evaluation

A structured diagnostic evaluation of hypopharyngeal and cervical esophageal carcinomas begins with a comprehensive clinical examination of the head and neck. Thorough inspection and systematic palpation are essential to assess the extent of the primary tumor and to detect possible cervical lymph node involvement. Careful evaluation of mucosal surfaces and nodal basins provides initial information regarding local extension and regional spread, forming the basis for subsequent diagnostic steps. Flexible nasolaryngoscopy represents a critical component of the initial assessment, as it allows direct visualization of the hypopharynx and larynx. This procedure enables identification of lesions that may not be evident on external examination alone and facilitates a more precise appraisal of tumor location and mucosal involvement. Its role in early evaluation is particularly relevant for planning further diagnostic procedures and determining the need for biopsy or advanced imaging [36].

Endoscopic assessment further refines diagnostic accuracy. Direct laryngoscopy and esophagoscopy provide detailed visualization of the larynx and esophagus, enabling the identification and targeted biopsy of suspicious lesions. These procedures are especially valuable in detecting synchronous tumors, which are relatively common in patients with head and neck malignancies. In this context, panendoscopy offers a comprehensive evaluation of the upper aerodigestive tract and is typically performed under general anesthesia. By incorporating laryngoscopy, esophagoscopy, and bronchoscopy, panendoscopy facilitates the detection of additional primary tumors and ensures a complete assessment of mucosal surfaces [37, 38].

Imaging modalities play a complementary and indispensable role in staging and treatment planning. Contrast-enhanced computed tomography of the neck and chest is routinely employed to evaluate the extent of the primary tumor and to assess regional lymph node involvement. Computed tomography provides detailed anatomical information that is essential for accurate staging and for determining resectability. Magnetic resonance imaging is particularly advantageous for assessing soft tissue involvement and defining the relationship between the tumor and adjacent structures. Owing to its superior contrast resolution compared with computed tomography, magnetic resonance imaging is especially useful in evaluating local invasion and involvement of surrounding tissues. Positron emission tomography combined with computed tomography integrates metabolic and anatomical data, thereby enhancing staging precision. This modality is particularly valuable for identifying distant metastases and refining overall disease staging [36].

Definitive diagnosis requires histologic confirmation. Incisional biopsy of the primary lesion remains the gold standard for establishing the diagnosis of carcinoma through histopathological examination. In parallel, fine needle aspiration of suspicious cervical lymph nodes provides a minimally invasive method for cytological assessment and facilitates the detection of metastatic disease. Together, these procedures confirm tumor histology and regional involvement, completing the diagnostic framework necessary for comprehensive staging and therapeutic planning [36].

Staging and Prognostic Factors

Staging in hypopharyngeal and cervical esophageal carcinomas is primarily based on the American Joint Committee on Cancer tumor–node–metastasis classification, which remains the standard framework for prognostic stratification and therapeutic planning. In hypopharyngeal carcinoma, the tumor–node–metastasis system emphasizes tumor size, extent of local invasion, regional lymph node

involvement, and the presence of distant metastases. Although this classification provides a structured and widely accepted method of staging, emerging evidence suggests that its prognostic performance may be enhanced by incorporating additional clinical and demographic variables. Nomograms that integrate factors such as age, race, and treatment modality have demonstrated improved prognostic discrimination compared with the traditional tumor–node–metastasis system alone [39]. Furthermore, the number of positive lymph nodes has been identified as a particularly strong prognostic indicator in hypopharyngeal squamous cell carcinoma, and proposals to incorporate positive lymph node number into the staging framework suggest that this modification could strengthen its predictive accuracy [40].

In cervical esophageal carcinoma, the tumor–node–metastasis system also constitutes the standard staging approach; however, several studies have proposed refinements to improve prognostic precision, particularly in the context of neoadjuvant therapy. The integration of tumor regression grade and lymph node status into a combined tumor regression grade–node system has been shown to provide superior prognostic stratification compared with conventional post-treatment tumor–node–metastasis stage groups following neoadjuvant therapy [41]. Similarly, the Primary Tumor Burden Score model, which incorporates the presence of residual cancer cells together with pretreatment tumor stage, has demonstrated greater prognostic accuracy than the post-treatment tumor–node–metastasis classification, especially in patients undergoing neoadjuvant chemoradiotherapy [42].

Among the core prognostic determinants included in staging systems, tumor size and depth of invasion remain fundamental variables. Both parameters are integral components of tumor classification and have consistently been associated with survival outcomes in hypopharyngeal and cervical esophageal carcinomas [23, 32]. Regional nodal involvement further represents a critical determinant of prognosis. In hypopharyngeal carcinoma, the number of positive lymph nodes has been identified as a strong predictor of survival [40], while in cervical esophageal carcinoma, the combination of lymph node status with tumor regression grade provides enhanced prognostic information following neoadjuvant therapy [41].

The presence of distant metastases significantly worsens prognosis and constitutes a defining element of the tumor–node–metastasis classification. Advanced nodal disease, in particular, has prompted the exploration of treatment strategies such as upfront neck dissection followed by chemoradiotherapy, which have been associated with improved outcomes in selected patients with hypopharyngeal carcinoma [9]. In surgically managed cases, margin status also plays a decisive role in long-term outcomes, as positive surgical margins are strongly associated with higher recurrence rates and reduced overall survival, particularly in hypopharyngeal carcinoma [43].

Beyond tumor-specific variables, patient-related factors contribute meaningfully to prognosis. Although not detailed in the cited studies, performance status is widely recognized as an important determinant of treatment tolerance, therapeutic selection, and overall outcomes. Collectively, these staging components and prognostic determinants illustrate the multifactorial nature of risk stratification in hypopharyngeal and cervical esophageal carcinomas and support ongoing efforts to refine existing classification systems to enhance predictive accuracy and guide individualized management [39, 41].

Therapeutic Strategies

The management of hypopharyngeal and cervical esophageal carcinomas requires a coordinated multidisciplinary approach that integrates surgical, medical, and supportive expertise. Surgical intervention remains a fundamental

component for resectable tumors, with collaboration between head and neck surgeons and thoracic surgeons being essential when disease extends across anatomical boundaries. Neck dissection plays a critical role in addressing regional lymph node involvement and has been associated with improved regional control in appropriately selected patients [9].

In parallel, radiation oncology and medical oncology contribute centrally to treatment planning, particularly in locally advanced disease. Concurrent chemoradiotherapy has become a standard organ-preservation strategy in many cases, demonstrating survival outcomes comparable to surgery in selected scenarios [23, 44]. This approach allows for the potential preservation of laryngeal and swallowing function while maintaining oncologic efficacy. Beyond definitive oncologic treatment, nutritional support and speech rehabilitation are indispensable components of comprehensive care. Post-treatment rehabilitation plays a decisive role in maintaining quality of life, particularly by supporting recovery of speech and swallowing functions after aggressive multimodal therapy [45].

In early-stage disease, defined as T1 to T2 without nodal involvement, treatment strategies focus on achieving local control while preserving organ function. Definitive radiotherapy represents a viable option, offering favorable local control rates with functional preservation. Alternatively, transoral or partial surgical resection remains a cornerstone for early-stage tumors, and adjuvant therapy may be administered when indicated to improve oncologic outcomes. The choice between these modalities is guided by tumor characteristics, patient factors, and institutional expertise [46].

For locally advanced disease, including T3 to T4 tumors or those with nodal involvement, more intensive treatment strategies are required. Concurrent chemoradiotherapy is frequently favored for organ preservation and has demonstrated efficacy in improving survival rates [43, 47]. In selected patients, radical surgery combined with neck dissection remains an important option, particularly when high-risk features are present or when organ-preservation strategies are not feasible. In such cases, surgery is often followed by adjuvant therapy to enhance disease control and improve both overall and disease-free survival [9, 43].

Extensive resections frequently necessitate complex reconstructive procedures to restore anatomical continuity and functional integrity. Following esophagectomy, techniques such as gastric pull-up and free jejunal graft reconstruction are employed to reestablish gastrointestinal continuity. In cases involving defects of the hypopharynx or cervical esophagus, the radial forearm free flap provides a reliable reconstructive option and has been associated with favorable functional outcomes [45].

Systemic therapy further complements local and regional treatment modalities. Platinum-based chemotherapy and taxane-based regimens constitute standard components of systemic treatment and are frequently administered in combination with radiotherapy to enhance therapeutic efficacy. In the setting of recurrent or metastatic disease, immunotherapy has emerged as a promising therapeutic avenue. Programmed death-1 inhibitors have demonstrated clinical benefit in advanced esophageal cancers, expanding the therapeutic landscape and offering new opportunities for disease control [26, 48].

Outcomes, Complications, and Follow-Up

Functional sequelae following treatment of hypopharyngeal and cervical esophageal carcinomas are frequent and may substantially affect long-term quality of life. In patients undergoing organ preservation strategies such as chemoradiotherapy for hypopharyngeal cancer, severe laryngeal dysfunction may develop despite anatomical preservation of the larynx. This dysfunction can result in permanent

tracheostomy dependence, thereby diminishing the intended functional advantages of organ preservation approaches [49]. In contrast, total pharyngo-laryngo-esophagectomy, which is often required in advanced disease, inevitably leads to permanent voice loss due to removal of the larynx, producing profound and irreversible alterations in communication and social integration [50].

Chronic dysphagia represents another common long-term complication. Persistent swallowing impairment may necessitate prolonged or permanent feeding tube dependence following surgery. Reconstructive strategies play a significant role in mitigating these consequences. The use of anterolateral thigh flaps for esophageal reconstruction has demonstrated promising results, including reduced fistula rates and improved oral alimentation, which may in turn decrease reliance on enteral feeding support [51].

Surgical management of these malignancies is also associated with substantial postoperative complications. Esophagectomies and extensive resections carry high rates of fistula formation and anastomotic leaks, both of which significantly affect morbidity and overall outcomes and require meticulous management [50, 51]. In addition, postoperative strictures may develop, leading to progressive luminal narrowing and necessitating further interventions to preserve esophageal patency and swallowing function [52].

Prognosis varies significantly according to stage at diagnosis. Patients identified at an early stage generally experience improved survival rates, and surgical approaches have been associated with better survival outcomes compared with non-surgical treatments in advanced hypopharyngeal cancer [53]. However, in advanced-stage hypopharyngeal and cervical esophageal carcinomas, overall prognosis remains poor, with five-year survival rates frequently below 30% [4]. Moreover, postoperative complications can further compromise long-term survival, underscoring the importance of minimizing surgical morbidity and optimizing perioperative management [52].

Given these risks, structured surveillance is essential. The first two years following treatment are particularly critical for detecting recurrence and the development of second primary tumors, making regular follow-up evaluations indispensable [54]. In parallel, long-term nutritional and functional rehabilitation remains a cornerstone of survivorship care. Continued nutritional support and efforts to restore swallowing and communication function are central to improving overall outcomes, and reconstructive techniques such as the anterolateral thigh flap have demonstrated effectiveness in enhancing functional recovery [51].

Conclusions

Hypopharyngeal and cervical esophageal carcinomas are anatomically complex and biologically aggressive malignancies characterized by early lymphatic dissemination, frequent cervical esophageal invasion, and a high propensity for regional nodal metastasis, including extra-capsular spread. These features, together with unfavorable molecular profiles such as TP53 mutations and EGFR overexpression, contribute to advanced-stage presentation, poor survival outcomes, and the need for comprehensive staging systems that integrate nodal burden, treatment response, and additional prognostic variables. The close anatomical relationship between the hypopharynx and cervical esophagus further complicates disease behavior and directly influences both prognosis and therapeutic planning.

Effective management of these tumors requires an individualized, multidisciplinary approach that balances oncologic control with functional preservation. While early-stage disease may be treated with organ-preserving strategies or

limited surgery, locally advanced tumors often necessitate aggressive multimodal therapy, including chemoradiotherapy, radical surgery, and complex reconstruction. Despite advances in systemic therapy and immunotherapy, long-term outcomes remain poor in advanced stages, and treatment-related morbidity significantly affects quality of life. Therefore, early detection, precise staging, optimized radiotherapy planning, and structured postoperative surveillance and rehabilitation are essential to improve survival and functional outcomes in this high-risk population.

References

1. Chen T, Wang C, Su LY, Lin MC, Yang TL, Lou PJ, et al. Impact of invasion into cervical esophagus for patients with hypopharyngeal squamous cell carcinoma. Oral Oncology [Internet]. 2021 Dec 29;125:105683. Available from: https://doi.org/10.1016/j.oraloncology.2021.105683
2. Guler O, Oymak E, Yazici G, Akagunduz O, Cetinayak O, Erpolat P, et al. The Treatment Outcomes of Patients with Cervical Esophageal Carcinoma Undergoing Definitive Chemoradiotherapy: A Multi-Institutional Analysis TROD 01-005. International Journal of Radiation Oncology Biology Physics [Internet]. 2022 Oct 22;114(3):e159–60. Available from: https://doi.org/10.1016/j.ijrobp.2022.07.1027
3. Chen C, Hang L, Liu Y, Xie J, Yang J. Oncological analysis and surgical outcomes in postcricoid carcinoma: a 14 years retrospective study. Cancers [Internet]. 2022 Jun 27;14(13):3146. Available from: https://doi.org/10.3390/cancers14133146
4. Bich TA, Vuong NL, Tu NCHTNC, Truong TM, Trung LV. Long-Term survival of patients after total pharyngolaryngoesophagectomy with gastric Pull-Up reconstruction for hypopharyngeal or laryngeal cancer invading cervical esophagus. Annals of Otology Rhinology & Laryngology [Internet]. 2022 Jun 3;132(5):511–8. Available from: https://doi.org/10.1177/00034894221098802
5. Moon J. Treatment of Choice for Resectable Cervical Esophageal Cancer: Surgery and Definitive Chemoradiotherapy with or without Dose Escalation. International Journal of Radiation Oncology Biology Physics [Internet]. 2022 Oct 22;114(3):e164. Available from: https://doi.org/10.1016/j.ijrobp.2022.07.1038
6. Sabbagh S, Iska S, Jabbal IS, Itani M, Mohanna M, Dominguez B, et al. A national analysis evaluating the role of neoadjuvant chemoradiotherapy in upper esophageal cancer. Journal of Clinical Oncology [Internet]. 2023 Jun 1;41(16_suppl):e16102. Available from: http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e16102
7. Gunasekera D, Goel S, Kao S, Krishnan S, Hodge JC, Foreman A, et al. The effectiveness of unimodality organ preservation surgery vs radiotherapy for early hypopharyngeal cancer: a systematic review protocol. JBI Evidence Synthesis [Internet]. 2025 Jan 7;23(4):756–64. Available from: https://doi.org/10.11124/jbies-24-00120
8. Poon W, Paterson C, McLoone P, Grose D, Schipani S, Lamb C, et al. Survival outcomes in hypopharyngeal cancer in the West of Scotland Cancer Network. Clinical Otolaryngology [Internet]. 2022 Nov 7;48(2):235–9. Available from: https://doi.org/10.1111/coa.14003
9. Yamauchi M, Sakai A, Ebisumoto K, Iijima H, Teramura T, Yamazaki A, et al. Evaluating clinical outcomes and

predictive factors of treatment approaches in T1–3N3B hypopharyngeal carcinoma: upfront neck dissection versus concurrent chemoradiotherapy. Head & Neck [Internet]. 2025 Jul 28;47(10):2856–66. Available from: https://doi.org/10.1002/hed.28261

10. Matsuda S, Takeuchi M, Kawakubo H, Kitagawa Y. Lymph node metastatic patterns and the development of multidisciplinary treatment for esophageal cancer. Diseases of the Esophagus [Internet]. 2023 Mar 1;36(4). Available from: https://doi.org/10.1093/dote/doad006
11. Kang Y, Park G, Park S, Kim T, Kim E, Heo Y, et al. Extra-Capsular spread of lymph node metastasis in oral, oropharyngeal and hypopharyngeal cancer: a comparative subsite analysis. Cancers [Internet]. 2024 Feb 3;16(3):659. Available from: https://doi.org/10.3390/cancers16030659
12. Von Döbeln G, Onjukka E, Ólafsdóttir HS, Jaraj SJ, Hedman M. Combining radiological and radiation oncology expertise in the delineation of hypopharyngeal tumours: potential effects on treatment volumes and patterns of failure. Clinical and Translational Radiation Oncology [Internet]. 2025 Jul 24;54:101022. Available from: https://doi.org/10.1016/j.ctro.2025.101022
13. De Leo A, Mendenhall W, Dagan R, Hitchcock K, Dziegielewski PT, Morris CG, et al. Sparing the larynx and hypopharynx with radiation therapy for squamous cell carcinoma of unknown primary site and predominant adenopathy in level IIA. Practical Radiation Oncology [Internet]. 2021 Jun 24;11(5):366–73. Available from: https://doi.org/10.1016/j.prro.2021.06.005
14. Simba H, Menya D, Mmbaga BT, Dzamalala C, Finch P, Mlombe Y, et al. The contribution of smoking and smokeless tobacco to oesophageal squamous cell carcinoma risk in the African oesophageal cancer corridor: Results from the ESCCAPE multicentre case-control studies. International Journal of Cancer [Internet]. 2023 Feb 3;152(11):2269–82. Available from: https://doi.org/10.1002/ijc.34458
15. Harris C, Mawlong A, Tapkire R, Albert S, Jagtap V. 790. RISK FACTORS FOR ESOPHAGEAL CANCER IN NORTHEAST INDIA: a MULTI-CENTRIC CASE-CONTROL STUDY. Diseases of the Esophagus [Internet]. 2024 Sep 1;37(Supplement_1). Available from: http://dx.doi.org/10.1093/dote/doae057.386
16. Kwon MJ, Kang HS, Choi HG, Kim JH, Kim JH, Bang WJ, et al. Risk for Esophageal Cancer Based on Lifestyle Factors–Smoking, Alcohol Consumption, and Body Mass Index: Insight from a South Korean Population Study in a Low-Incidence Area. Journal of Clinical Medicine [Internet]. 2023 Nov 14;12(22):7086. Available from: https://doi.org/10.3390/jcm12227086
17. Greene N, Reyes-Guzman C, Baker L, Meador E, Noone AM, Howlader N. Impact of Alcohol Consumption on Selected Cancer Incidence Trends among Adults in the United States, 2008 to 2019. Cancer Epidemiology Biomarkers & Prevention [Internet]. 2025 Sep 8;34(11):2095–103. Available from: https://doi.org/10.1158/1055-9965.epi-25-0243
18. Jun S, Park H, Kim UJ, Lee HA, Park B, Lee SY, et al. The Combined Effects of Alcohol consumption and smoking on Cancer Risk by Exposure Level: A Systematic Review and Meta-Analysis. Journal of Korean Medical Science

[Internet]. 2024 Jan 1;39(22):e185. Available from: https://doi.org/10.3346/jkms.2024.39.e185

19. Cai Y, Lin J, Wei W, Chen P, Yao K. Burden of esophageal cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019. Frontiers in Public Health [Internet]. 2022 Sep 6;10:952087. Available from: https://doi.org/10.3389/fpubh.2022.952087
20. Tsai MC, Chou YC, Lee YK, Hsu WL, Tang CS, Chen SY, et al. Secular Trends in Incidence of Esophageal Cancer in Taiwan from 1985 to 2019: An Age-Period-Cohort Analysis. Cancers [Internet]. 2022 Nov 27;14(23):5844. Available from: https://doi.org/10.3390/cancers14235844
21. Porschen R, Fischbach W, Gockel I, Hollerbach S, Hölscher A, Jansen PL, et al. Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus. United European Gastroenterology Journal [Internet]. 2024 Jan 29;12(3):399–411. Available from: https://doi.org/10.1002/ueg2.12523
22. Ooki A, Osumi H, Chin K, Watanabe M, Yamaguchi K. Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma. Therapeutic Advances in Medical Oncology [Internet]. 2023 Jan 1;15:17588359221138377. Available from: https://doi.org/10.1177/17588359221138377
23. Zhang L, Shao J, Liu Z, Pan J, Li B, Yang Y, et al. Occurrence and prognostic value of perineural invasion in esophageal squamous cell cancer: a retrospective study. Annals of Surgical Oncology [Internet]. 2021 Aug 23;29(1):586–97. Available from: https://doi.org/10.1245/s10434-021-10665-z
24. Zhao Y, Zhao H, Zhao M, Yu Y, Qi X, Wang J, et al. Latest insights into the global epidemiological features, screening, early diagnosis and prognosis prediction of esophageal squamous cell carcinoma. World Journal of Gastroenterology [Internet]. 2024 May 27;30(20):2638–56. Available from: https://doi.org/10.3748/wjg.v30.i20.2638
25. Jiang G, Wang Z, Cheng Z, Wang W, Lu S, Zhang Z, et al. The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma. Nature Communications [Internet]. 2024 Oct 17;15(1):8988. Available from: https://doi.org/10.1038/s41467-024-53164-x
26. Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, et al. Esophageal and esophagogastric junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network [Internet]. 2023 Apr 1;21(4):393–422. Available from: https://doi.org/10.6004/jnccn.2023.0019
27. McDowell L, King MT, Hutcheson KA, Ringash J, Yom SS, Corry J, et al. A hard truth to swallow: critically evaluating the MD Anderson Dysphagia inventory (MDADI) as an endpoint in human papillomavirus-associated oropharyngeal cancer trials. International Journal of Radiation Oncology Biology Physics [Internet]. 2024 May 11;120(3):805–22. Available from: https://doi.org/10.1016/j.ijrobp.2024.05.005
28. Oguma J, Ozawa S, Ishiyama K, Daiko H. Clinical significance of sarcopenic dysphagia for patients with esophageal cancer undergoing esophagectomy: A review. Annals of Gastroenterological Surgery [Internet]. 2022 Jul 28;6(6):738–

45. Available from: https://doi.org/10.1002/ags3.12603

29. Mes S, Van Kalkeren T, Jacobs RJ, Coene IMJH, Langeveld APM, Locher H. Hiding in plain sight: an unusual case of progressive dysphagia, dyspnea and dysphonia. Dysphagia [Internet]. 2020 Sep 1;36(4):754–7. Available from: https://doi.org/10.1007/s00455-020-10183-2
30. Zebralla V, Wichmann G, Pirlich M, Hammermüller C, Berger T, Zimmermann K, et al. Dysphagia, voice problems, and pain in head and neck cancer patients. European Archives of Oto-Rhino-Laryngology [Internet]. 2021 Jan 16;278(10):3985–94. Available from: https://doi.org/10.1007/s00405-020-06584-6
31. Gillman A, Reynolds JV, Hayes M, Walshe M, Regan J. 545. The nature, severity and impact of curative oesophageal resection for oesophageal cancer on swallowing throughout survivorship: preliminary findings. Diseases of the Esophagus [Internet]. 2022 Sep 1;35. Available from: https://doi.org/10.1093/dote/doac051.545
32. Ozaki A, Mine S, Yoshino K, Fujiwara D, Nasu M, Hashiguchi T, et al. Outcomes of esophagectomy for patients with esophageal squamous cell carcinoma accompanied by recurrent laryngeal nerve palsy at diagnosis. Esophagus [Internet]. 2021 Oct 27;19(2):233–9. Available from: https://doi.org/10.1007/s10388-021-00890-6
33. Balaji A, Thiagarajan S, Mallik A, Menon N, Chakraborthy A, Chaukar D. Results of pretreatment swallowing evaluation in patients with stage III/IV laryngeal and hypopharyngeal carcinoma. European Archives of Oto-Rhino-Laryngology [Internet]. 2020 Nov 9;278(8):3011–8. Available from: https://doi.org/10.1007/s00405-020-06460-3
34. Fujiwara K, Taira K, Donishi R, Koyama S, Morisaki T, Fukuhara T, et al. Preoperative predictors of dysphagia after transoral surgery. International Journal of Clinical Oncology [Internet]. 2021 Jan 18;26(5):835–40. Available from: https://doi.org/10.1007/s10147-021-01860-9
35. Varghese J, Aithal VU, Sharan K, Maiya AG, Rajashekhar B. Profiling of swallowing function in head and neck cancer patients prior to radiation therapy-Findings from a tertiary hospital in South India. Preventive Medicine Reports [Internet]. 2024 Apr 2;41:102713. Available from: https://doi.org/10.1016/j.pmedr.2024.102713
36. Gule-Monroe M, Calle S, Policeni B, Juliano AF, Agarwal M, Chow LQM, et al. ACR Appropriateness Criteria® Staging and Post-Therapy Assessment of Head and Neck Cancer. Journal of the American College of Radiology [Internet]. 2023 Nov 1;20(11):S521–64. Available from: https://doi.org/10.1016/j.jacr.2023.08.008
37. Van De Ven S, De Graaf W, Bugter O, Spaander MCW, Nikkessen S, De Jonge PJF, et al. Screening for synchronous esophageal second primary tumors in patients with head and neck cancer. Diseases of the Esophagus [Internet]. 2021 Jun 1;34(10). Available from: https://doi.org/10.1093/dote/doab037
38. Nouraei S. Should diagnostic rigid oesophagoscopy continue to form part of panendoscopy? Clinical Otolaryngology [Internet]. 2024 Dec 23;50(2):396–8. Available from: https://doi.org/10.1111/coa.14266
39. Yang H, Zeng M, Cao S, Jin L. Nomograms predicting prognosis for locally advanced hypopharyngeal

squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology [Internet]. 2021 Oct 14;279(6):3041–52. Available from: https://doi.org/10.1007/s00405-021-07109-5

40. Pang W, Luo Y, Li J, Cheng D, Rao Y, Mao M, et al. The prognostic prediction value of positive lymph nodes numbers for the hypopharyngeal squamous cell carcinoma. Frontiers in Medicine [Internet]. 2022 Jul 4;9:898483. Available from: https://doi.org/10.3389/fmed.2022.898483
41. Wong I, Chung J, Zhang R, Gao X, Lam K, Kwong D, et al. A novel tumor staging system incorporating tumor regression grade (TRG) with lymph node status (YPN-Category) results in better prognostication than YPTNM stage groups after neoadjuvant therapy for esophageal squamous cell carcinoma. Annals of Surgery [Internet]. 2022 Jul 25;276(5):784–91. Available from: https://doi.org/10.1097/sla.0000000000005636
42. Huang X, Tang H, Tan L, Hou Y. 448. The primary tumor burden score: a novel clinicopathological staging tool for patients with esophageal carcinoma receiving neoadjuvant chemoradiotherapy plus surgery. Diseases of the Esophagus [Internet]. 2022 Sep 1;35. Available from: https://doi.org/10.1093/dote/doac051.448
43. Lin Y, Hsiao J, Wu Y, Chang J, Ou CY, Lee W, et al. Distinct failure patterns in hypopharyngeal cancer patients receiving Surgery-Based versus Radiation-Based treatment. Annals of Surgical Oncology [Internet]. 2022 Nov 6;30(2):1169–81. Available from: https://doi.org/10.1245/s10434-022-12744-1
44. Zheng L, Fang S, Ye L, Cai W, Xiang W, Qi Y, et al. Optimal treatment strategy and prognostic analysis for hypopharyngeal squamous-cell carcinoma patients with T3-T4 or node-positive: A population-based study. European Journal of Surgical Oncology [Internet]. 2023 Mar 22;49(7):1162–70. Available from: https://doi.org/10.1016/j.ejso.2023.03.215
45. Bandidwattanawong C. Multi-disciplinary management of esophageal carcinoma: Current practices and future directions. Critical Reviews in Oncology/Hematology [Internet]. 2024 Mar 9;197:104315. Available from: https://doi.org/10.1016/j.critrevonc.2024.104315
46. Panda S, Sakthivel P, Gurusamy KS, Sharma A, Thakar A. Treatment options for resectable hypopharyngeal squamous cell carcinoma: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE [Internet]. 2022 Nov 29;17(11):e0277460. Available from: https://doi.org/10.1371/journal.pone.0277460
47. Sabino F, Filho M, Carneiro M, Reisner D, Guaraldi D, Pinto L, et al. 625. Phase ii trial of induction chemotherapy followed by chemoradiation and minimally invasive surgery for locally advanced carcinoma of the esophagus. Diseases of the Esophagus [Internet]. 2024 Sep 1;37(Supplement_1). Available from: https://doi.org/10.1093/dote/doae057.332
48. Gui L, Xie Z, Wang X, Liu S, Yi J, An C, et al. Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials. Journal of Clinical Oncology [Internet]. 2024 Jun 1;42:6078. Available from: http://dx.doi.org/10.1200/jco.2024.42.16_suppl.6078

49. Batchelor C, Flukes S. Tracheostomy dependence following "organ preservation" (chemo)radiation protocol for laryngeal and hypopharyngeal cancers. Head & Neck [Internet]. 2022 Sep 19;44(12):2779–85. Available from: https://doi.org/10.1002/hed.27195
50. Zheng Y, Lee J. 243. Total pharyngolaryngoesophagectomy for cervical esophageal cancer: experience of a single tertiary medical center. Diseases of the Esophagus [Internet]. 2025 Aug 1;38(Supplement_1). Available from: https://doi.org/10.1093/dote/doaf061.159
51. Amendola F, Spadoni D, Lundy JB, Cottone G, Velazquez-Mujica J, Platsas L, et al. Reducing complications in reconstruction of the cervical esophagus with anterolateral thigh flap: The five points protocol. Journal of Plastic Reconstructive & Aesthetic Surgery [Internet]. 2022 Apr 28;75(9):3340–5. Available from: https://doi.org/10.1016/j.bjps.2022.04.043
52. Broadbent A, Rahman S, Grace B, Walker R, Noble F, Kelly J, et al. The effect of surgical complications on long-term prognosis following oesophagectomy. European Journal of Surgical Oncology [Internet]. 2023 May 18;49(10):106930. Available from: https://doi.org/10.1016/j.ejso.2023.05.005
53. Machuca M, Ng D, Terng S, Wu W, Cheng C. Survival and complications with a surgical approach in advanced hypopharyngeal cancer. Journal of Surgical Oncology [Internet]. 2021 Feb 23;123(7):1540–6. Available from: https://doi.org/10.1002/jso.26440
54. Huh G, Chung E, Kim WS, Kwon SK, Sung M, Keam B, et al. Beyond complete remission: A comparative analysis of long-term laryngeal function in patients with hypopharyngeal and laryngeal cancer following radiotherapy and concurrent chemoradiation. Head & Neck [Internet]. 2024 Sep 14;47(2):495–503. Available from: https://doi.org/10.1002/hed.27935